

# Jack Satsangi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5438474/publications.pdf>

Version: 2024-02-01

76  
papers

6,000  
citations

126858

33  
h-index

102432

66  
g-index

79  
all docs

79  
docs citations

79  
times ranked

11135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 256-261.	9.4	943
2	Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. <i>Nature Genetics</i> , 1996, 14, 199-202.	9.4	682
3	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet</i> , The, 2016, 387, 156-167.	6.3	607
4	Fine-mapping inflammatory bowel disease loci to single-variant resolution. <i>Nature</i> , 2017, 547, 173-178.	13.7	473
5	Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. <i>Nature Genetics</i> , 2017, 49, 262-268.	9.4	250
6	The Impact of Different DNA Extraction Kits and Laboratories upon the Assessment of Human Gut Microbiota Composition by 16S rRNA Gene Sequencing. <i>PLoS ONE</i> , 2014, 9, e88982.	1.1	236
7	Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. <i>Nature Medicine</i> , 2015, 21, 1018-1027.	15.2	212
8	Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1716-1730.	0.6	180
9	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	9.4	165
10	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. <i>Nature Genetics</i> , 2017, 49, 186-192.	9.4	153
11	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	3.8	136
12	The role of glycosylation in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 588-600.	8.2	123
13	Advances in IBD genetics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 372-385.	8.2	114
14	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 273-282.	3.7	91
15	Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2016, 111, 1796-1805.	0.2	88
16	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. <i>Digestive Diseases</i> , 2021, 39, 119-139.	0.8	88
17	Mitochondrial DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During Active IBD. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2113-2122.	0.9	87
18	Crohn's disease. <i>BMJ</i> , The, 2014, 349, g6670-g6670.	3.0	74

#	ARTICLE	IF	CITATIONS
19	Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1385-1393.	0.6	74
20	Pathogenesis of Crohn's disease. <i>F1000prime Reports</i> , 2015, 7, 44.	5.9	73
21	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	3.7	70
22	Pooled Sequencing of 531 Genes in Inflammatory Bowel Disease Identifies an Associated Rare Variant in <i>BTNL2</i> and Implicates Other Immune Related Genes. <i>PLoS Genetics</i> , 2015, 11, e1004955.	1.5	59
23	Precision medicine in inflammatory bowel disease: concept, progress and challenges. <i>F1000Research</i> , 2020, 9, 54.	0.8	59
24	Genetic sharing and heritability of paediatric age of onset autoimmune diseases. <i>Nature Communications</i> , 2015, 6, 8442.	5.8	58
25	Open : Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-up in the PYRAMID Registry. <i>American Journal of Gastroenterology</i> , 2018, 113, 872-882.	0.2	58
26	&lt;p&gt;Fecal microbiota profiles in treatment-na&amp;iuml;ve pediatric inflammatory bowel disease &amp;ndash; associations with disease phenotype, treatment, and outcome&lt;/p&gt;. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 37-49.	1.0	58
27	Systemic Inflammation in Preclinical Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 161, 1526-1539.e9.	0.6	58
28	De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 63-79.	3.7	56
29	Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor ACE2 and TMPRSS2 in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2020, 159, 1151-1154.e2.	0.6	56
30	Biomarkers in Search of Precision Medicine in IBD. <i>American Journal of Gastroenterology</i> , 2016, 111, 1682-1690.	0.2	45
31	Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16&acirc;50years. <i>Journal of Crohn's and Colitis</i> , 2014, 9, 41-9.	0.6	43
32	Transcription and DNA Methylation Patterns of Blood-Derived CD8+ T Cells Are Associated With Age and Inflammatory Bowel Disease But Do Not Predict Prognosis. <i>Gastroenterology</i> , 2021, 160, 232-244.e7.	0.6	42
33	Review article: impact of cigarette smoking on intestinal inflammation&acirc;direct and indirect mechanisms. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1268-1285.	1.9	37
34	Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. <i>Nature Communications</i> , 2020, 11, 995.	5.8	37
35	Promoter methylation of the <i>MGAT3</i> and <i>BACH2</i> genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. <i>Clinical Epigenetics</i> , 2018, 10, 75.	1.8	32
36	Purine metabolism controls innate lymphoid cell function and protects against intestinal injury. <i>Immunology and Cell Biology</i> , 2018, 96, 1049-1059.	1.0	30

#	ARTICLE	IF	CITATIONS
37	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1097-1103.	0.6	29
38	Inflammatory Bowel Disease Through the Lens of Single-cell RNA-seq Technologies. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1658-1668.	0.9	27
39	Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease-Associated Colorectal Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5133-5142.	3.2	26
40	The type III intermediate filament vimentin regulates organelle distribution and modulates autophagy. <i>PLoS ONE</i> , 2019, 14, e0209665.	1.1	26
41	Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 73-84.	1.9	24
42	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2741-2752.e6.	2.4	18
43	Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019, 19, 82.	0.8	17
44	The Inflammatory Bowel Disease Drug Azathioprine Induces Autophagy via mTORC1 and the Unfolded Protein Response Sensor PERK. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1481-1496.	0.9	17
45	Predicting Outcome in Acute Severe Colitis - Controversies in Clinical Practice in 2021. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1211-1221.	0.6	17
46	Shared activity patterns arising at genetic susceptibility loci reveal underlying genomic and cellular architecture of human disease. <i>PLoS Computational Biology</i> , 2018, 14, e1005934.	1.5	17
47	Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1255-1268.	0.6	17
48	Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease. <i>JCI Insight</i> , 2022, 7, .	2.3	17
49	Changes to Serum Sample Tube and Processing Methodology Does Not Cause Inter-Individual Variation in Automated Whole Serum N-Glycan Profiling in Health and Disease. <i>PLoS ONE</i> , 2015, 10, e0123028.	1.1	15
50	Systematic meta-analyses and field synopsis of genetic and epigenetic studies in paediatric inflammatory bowel disease. <i>Scientific Reports</i> , 2016, 6, 34076.	1.6	12
51	Genetics of inflammatory bowel disease: from bench to bedside?. <i>Acta Odontologica Scandinavica</i> , 2001, 59, 187-192.	0.9	11
52	Copy number variation of scavenger-receptor cysteine-rich domains within DMBT1 and Crohn's disease. <i>European Journal of Human Genetics</i> , 2016, 24, 1294-1300.	1.4	10
53	Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. <i>Gut</i> , 2021, 70, 2398-2400.	6.1	9
54	How to Apply for and Secure EU Funding for Collaborative IBD Research Projects. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 363-370.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Mucosal Gene Transcript Signatures in Treatment Na <sup>+</sup> ve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. <i>Clinical and Experimental Gastroenterology</i> , 2022, Volume 15, 5-25.	1.0	5
56	Blood-based DNA methylation in Crohn's disease and severity of intestinal inflammation. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 76-76.	1.5	4
57	De-escalation of medical therapy in inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2020, 55, 73-81.	1.7	4
58	Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic. <i>Gastroenterology</i> , 2021, 160, 1883-1884.	0.6	3
59	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. <i>Gut</i> , 2022, 71, 1919.2-1922.	6.1	3
60	Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. <i>United European Gastroenterology Journal</i> , 2022, 10, 485-495.	1.6	3
61	The role of genetics in Crohn's disease: how could it influence future therapies?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1075-1077.	1.4	2
62	Just Another Flare of Ulcerative Colitis?. <i>Gastroenterology</i> , 2020, 158, e11-e12.	0.6	2
63	Steering a Course through the COVID-19 Pandemic: Should the SECURE-IBD Registry Influence Prescribing for Patients with Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2021, 160, 1867-1870.	0.6	2
64	Anti-SARS-CoV-2 Antibody Responses in Patients With IBD Treated With Biologics: Are We Finding CLARITY?. <i>Gastroenterology</i> , 2021, 161, 2057-2059.	0.6	2
65	Molecular genetics in gastroenterology: from research success to clinical application?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2005, 2, 118-119.	1.7	1
66	Reply to Daly and Rioux response. <i>European Journal of Human Genetics</i> , 2006, 14, 261-261.	1.4	1
67	Two-Stage Genome-Wide Search in Inflammatory Bowel Disease: Strong Evidence for Susceptibility Loci on Chromosomes 3, 7 and 12. <i>Clinical Science</i> , 1997, 93, 18P-19P.	0.0	0
68	What do the terms "genetic predisposition" and "genetic heterogeneity" mean in relation to inflammatory bowel disease?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S31-S32.	0.9	0
69	A plea for TDM-based optimisation for treatment of Crohn's disease "Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 81-82.	3.7	0
70	Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 76-78.	2.4	0
71	PWE-026...Endoscopy is superior to stool frequency in predicting response to steroids in acute ulcerative colitis. , 2018, , .		0
72	O66...Outcome of investigation for suspected malignancy in patients with iron deficiency anaemia without gastrointestinal symptoms. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
73	Reply. Gastroenterology, 2021, 160, 2622-2623.	0.6	0
74	PWE-019â€¦Day of admission results predict outcome in acute ulcerative colitis. , 2018, , .		0
75	Probing the Microbiome to Predict Response to Biologic Therapy in Inflammatory Bowel Diseaseâ€”One Step Closer to Precision Medicine?. Gastroenterology, 2022, , .	0.6	0
76	Letter: rationalising aminosalicylates in inflammatory bowel diseaseâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1621-1621.	1.9	0